Answers are grounded in this paper and cite their sources.
Evaluates molecular profiling outcomes in glioma, suggesting improvements in personalized treatment access.
Advances in molecular profiling have led to improved understanding of glioma heterogeneity. Results have been used to inform diagnostic classification and targeted treatment strategies. Validation of these tests is necessary in the development of biomarkers that can aid in treatment decision, allowing for personalized medicine in neuro-oncologic diseases. Although not all populations have benefitted equally from awareness of and access to testing, opportunities arise regarding incorporating this testing into the standard of care for patients with glioma.
No takes yet. Share an insight, caveat, or question.
Porter et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: